Page 11 - Cassava Sciences News Today

Texas Biotech Exceeds Alzheimers Trial Enrollment Target

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimers.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected...

07.11.2023 - Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimers.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week ...

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimers disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end...

NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc.  .   Such investors are advised to contact Robert S. Willoughby at...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such...

Playing the blame game does not make for an effective turnaround strategy.

Cassava Sciences, Inc. (NASDAQ:SAVA – Get Free Report)’s share price was down 4.6% on Thursday . The company traded as low as $17.45 and last traded at $17.72. Approximately 231,527 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,024,391 shares. The stock had previously closed at $18.58. […]

Citing questions about the integrity of the process, the university said that “no final action” had been taken.

Report on Research Compliance 20, no. 11 (November, 2023) City University of New York (CUNY ) has accused neuroscientist Hoau-Yan Wang, a CUNY faculty member and longtime...